文献速递心境障碍焦虑、强迫与应激相关障碍

2-花生四烯酸甘油酯调节焦虑与应激适应:从基础到新型治疗

2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics.
PubMed 文献 · Biol Psychiatry · 2020-03-17

本文综述2-花生四烯酸甘油酯(2-AG)信号传导的生物化学与生理学,以及支持其在焦虑相关结局和应激适应中调控作用的临床前证据。文章回顾了支持单酰甘油脂肪酶(MAGL)抑制用于治疗情感、创伤相关和应激相关障碍的临床前证据,描述MAGL抑制剂药物开发现状,并讨论可能影响其疗效的生物学因素及临床推进相关问题。作者对药理学增强2-AG作为情感与应激相关神经精神障碍的机制新颖治疗途径持谨慎乐观态度。

要点

  • 2-AG是含量最丰富且效力最强的内源性大麻素配体,MAGL抑制可增强其信号传导。
  • 临床前证据支持MAGL抑制用于情感、创伤相关和应激相关障碍。
  • MAGL抑制剂开发正从临床前向临床、从理论向实践过渡。

核心结论

  • 药理学增强2-AG可能成为治疗情感与应激相关神经精神障碍的机制新颖治疗途径,作者对此持谨慎乐观态度。

研究设计与样本

  • 本文为综述,回顾2-AG信号传导的生物化学与生理学及临床前证据,并描述MAGL抑制剂药物开发现状。

主要发现

  • 临床前证据支持2-AG系统在焦虑相关结局与应激适应调控中的作用。
  • 临床前证据支持MAGL抑制用于治疗情感、创伤相关和应激相关障碍。

临床怎么用

  • MAGL抑制通过增强2-AG信号传导,可能为情感与应激相关障碍提供机制新颖的药理干预方向。

局限性

  • 本文为综述,未报告原始研究数据;MAGL抑制剂尚处于从临床前向临床过渡阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past decade there has been a surge of interest in the development of endocannabinoid-based therapeutic approaches for the treatment of diverse neuropsychiatric conditions. Although initial preclinical and clinical development efforts focused on pharmacological inhibition of fatty acid amide hydrolase to elevate levels of the endocannabinoid anandamide, more recent efforts have focused on inhibition of monoacylglycerol lipase (MAGL) to enhance signaling of the most abundant and efficacious endocannabinoid ligand, 2-arachidonoylglycerol (2-AG). We review the biochemistry and physiology of 2-AG signaling and preclinical evidence supporting a role for this system in the regulation of anxiety-related outcomes and stress adaptation. We review preclinical evidence supporting MAGL inhibition for the treatment of affective, trauma-related, and stress-related disorders; describe the current state of MAGL inhibitor drug development; and discuss biological factors that could affect MAGL inhibitor efficacy. Issues related to the clinical advancement of MAGL inhibitors are also discussed. We are cautiously optimistic, as the field of MAGL inhibitor development transitions from preclinical to clinical and theoretical to practical, that pharmacological 2-AG augmentation could represent a mechanistically novel therapeutic approach for the treatment of affective and stress-related neuropsychiatric disorders.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bedse G, Hill MN, Patel S, et al. 2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics. Biol Psychiatry. 2020. PMID: 32197779. doi:10.1016/j.biopsych.2020.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。